about
Soy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future PerspectivesThe fate of chemoresistance in triple negative breast cancer (TNBC)Aetio-pathogenesis of breast cancerChallenges in the Treatment of Triple Negative and HER2-Overexpressing Breast CancerCdc20 and securin overexpression predict short-term breast cancer survival.Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.Triple Negative Breast Cancer - An OverviewIL-32 promotes breast cancer cell growth and invasivenessTriple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsMutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.Decreased HCRP1 expression is associated with poor prognosis in breast cancer patientsBasal-like and triple-negative breast cancers: searching for positives among many negativesMammary cells with active Wnt signaling resist ErbB2-induced tumorigenesisSilencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.Axl receptor tyrosine kinase expression in breast cancerAMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer.Novel therapy for locally advanced triple-negative breast cancer.Inositol 1, 4, 5-trisphosphate-dependent nuclear calcium signals regulate angiogenesis and cell motility in triple negative breast cancer.The hypoxic tumor microenvironment: A driving force for breast cancer progression.The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cellsIGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumorsMyeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cellsNa+/H+ exchanger NHE1 regulation modulates metastatic potential and epithelial-mesenchymal transition of triple-negative breast cancer cells.Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.The molecular diversity of Luminal A breast tumors.Identification and Testing of Novel CARP-1 Functional Mimetic Compounds as Inhibitors of Non-Small Cell Lung and Triple Negative Breast Cancers.Triple Negative Breast Cancer: Nanosolutions for a Big Challenge.Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.Divergent Synthesis of Chondroitin Sulfate Disaccharides and Identification of Sulfate Motifs that Inhibit Triple Negative Breast Cancer.CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts.Model of tumor-associated epigenetic changes of HER2, ER, and PgR expression in invasive breast cancer phenotypes.The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.Activators of AMPK: not just for type II diabetes.CD73-adenosine: a next-generation target in immuno-oncology.Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
P2860
Q26772042-2977F025-8241-4540-922A-2C0EB4DF6A25Q26775232-DD1A82F4-8DBA-43CC-8767-564F6C6934BAQ26825073-59018EC7-04BC-474E-BD09-66AE77C6204DQ33576608-17C6A3BA-8570-4197-97E1-13D5C9452AACQ33750165-076B4749-EB6E-406D-81F0-A86453A4B873Q33866151-76CF009E-55F2-4DDA-84C4-E3D6A9C25465Q34274285-8E43E11A-397F-45A4-BDD5-82697ACD04F5Q34582585-76AA42E5-B9A7-4D68-839B-2BA328E8B1BCQ34646376-90CD20A7-2BE0-4CBE-81AE-89824EA7319DQ34654793-6359C309-725E-4E66-9D3C-3A6181C37D51Q34732984-2BD4A2CE-6FCA-4E20-A1FA-2BF7D04577E2Q35005793-E644985E-8B49-4AD2-8176-5A19999236ACQ35050344-FCA7467F-4BDA-4B72-8E74-4ABC001BFDB7Q35674830-3D57D443-54FC-4E56-90B0-A43DA6F0F8F9Q35996780-D4F40C6E-B19C-41FB-9EAE-2050A9C52652Q36020830-35AED341-9E39-4EF6-8839-7CB7B55B57CDQ36094096-13952E1B-19D6-4C6E-92DF-F0C9316049F1Q36334094-5A5C2C49-414F-41E6-B7A3-BBA59D919BC5Q36368931-1D740B3D-A4FA-4D8A-A1CD-0245E08FC6B0Q36544052-E0C54E9C-FCA8-4ED1-A2EC-5ECB315C27DCQ36664343-6F74E6E0-7988-4A49-8A7B-A5408F084D3DQ36751571-B5AB7F4C-0C1A-4B76-AABF-8E6EF9FFD06EQ37051417-DE46AC34-0F38-4DDD-95D0-E1DB8E1CB11DQ37071461-02425513-24DE-4B15-877E-DF963F430D08Q37225224-FDED322C-2BF2-4232-BB03-F236335B2DDCQ37237114-58EC4DF5-3961-4969-823A-F060FD468991Q37298868-3B9D70D9-9579-47CE-BC54-0E49F274C9BAQ37386051-C6031989-5A34-4F5A-B95F-BCCE4E2B4684Q37422972-966984DF-DE54-4E56-A48A-10678E19F75FQ37444430-03A1C195-F7FB-41AE-B337-8A7E29806B97Q37487789-223A780A-AB58-400A-81AA-913633076182Q37502422-068719B7-BF52-40CE-8185-B255A9AB3F65Q37687393-696E54A3-FC29-48B8-AECF-0BE8D3E70CF6Q37703365-F806C3D5-D6B3-4A5F-914F-F146395346F1Q38103751-7B461782-EFC1-4087-83C4-0C87A752549EQ38192017-6DE273B4-A11D-46D3-8C53-77F0B5F0D642Q38209586-2C128407-9BE2-40FF-B427-544A75AED194Q38243893-21214C2F-B700-4CD6-9A09-3C7A1C9AD3D8Q38711094-30096792-4AD6-4214-8C97-9642E6A97A2CQ38720294-3C69E7A4-D9EF-41EF-912A-DCB39A30CB26
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Therapeutic targets in triple negative breast cancer.
@en
type
label
Therapeutic targets in triple negative breast cancer.
@en
prefLabel
Therapeutic targets in triple negative breast cancer.
@en
P2093
P2860
P1476
Therapeutic targets in triple negative breast cancer.
@en
P2093
Alexander Swarbrick
Anna McLean
Aurelie Cazet
Ewan K A Millar
Jane M Beith
Richard West
Samantha R Oakes
Sandra A O'Toole
P2860
P304
P356
10.1136/JCLINPATH-2012-201361
P407
P577
2013-02-22T00:00:00Z